Source Articles
immunotherapy NOS
Showing 2 study arms
with grade ≥3 adverse event data (treatment-related and RT-related).
Click a column header to sort.
Note on patient counts: some articles reported only percentages rather
than absolute numbers. Where this occurred, the number of patients — including those with
grade ≥3 adverse events — was derived by applying the reported percentage to the total arm
size, which may produce a non-integer value. These figures have been rounded to the nearest
integer for display.
| 1st Author | Year | Study Type | Title | DOI | clinical trial number | number of patients | median/mean age | tumor type | treatment setting | drug group | drug name | if other, please specify | number of SBRT courses | intracranial / extracranial | treated site | If other treated site, please specify | median/mean total RT dose [Gy] | minimum total RT dose [Gy] | maximum total RT dose [Gy] | median/mean number of fractions | minimum number of fractions | maximum number of fractions | median/mean dose per fraction [Gy] | minimum dose per fraction [Gy] | maximum dose per fraction [Gy] | toxicity type | patients with acute G>=3 toxicity | patients with late G>=3 toxicity | patients with G>=3 toxicity, timing unspecified | G>=3 AEs | patients with G>=3 AEs | details on G>=3 toxicity | details on G>=3 toxicity in RT field |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| van 't Land et al. | 2022 | Prospective | Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed Mycobacterium Obuense (IMM-101) in Patients with Locally Advanced Pancreatic Cancer | 10.3390/cancers14215299 | NL7578 | 20 | 63 | pancreas | primary | immunotherapy NOS | Unknown drug | IMM-101 vaccination | 20 | extra-cranial | other | Pancreas | 40 | 40 | 40 | 5 | 5 | 5 | 8 | 8 | 8 | Treatment-rel. | — | — | 3 | G3: 3 AEs | G3: 3 pts | G3: GI haemorrhage | — |
| Rodríguez-Ruiz et al. | 2018 | Prospective | Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients | 10.1093/annonc/mdy089 | — | 6 | 54 | Prostate cancer, Head and neck cancer, other | any | immunotherapy NOS | Unknown drug | dendritic cell vaccines, and hiltonol intratumoral injection | 6 | extra-cranial | lung, liver, LN unspecified, other | peritoneum node, also other sites irradiated but not specified (only specified sites are those that received Hiltonol and SBRT) | 24 | 24 | 24 | 3 | 3 | 3 | 8 | 8 | 8 | Treatment-rel. | — | — | 0 | — | — | — | — |